Med Tech
Capitol Street monitors, analyzes, and details the healthcare policy actions and trends that impact medical technology and diagnostic players. This includes Medicare coverage and reimbursement developments, MCIT proposals and hospital purchasing and other marketplace trends such as commercial insurance’s surgical prior authorization.
We identify impactful payment and regulatory trends that are often lost on experts, and those that simply look at one or two aspects of healthcare.
How Capitol Street Clients Use Our Medical Device and Diagnostic Research
We provide real-time and in-depth analysis of healthcare legislation, trends among payors and healthcare stakeholders, and policies that originate from healthcare agencies (CMS, FTC, FDA), think tanks and other bodies (MedPAC, BPC, AEI, Brookings) and Capitol Hill (e.g., ARPA-H, Cures, MDUFA).
We also preview, review and analyze Supreme Court and lower court case proceedings that are relevant to our healthcare clients.
For example, our clients use Capitol Street to piece together Hospital Inpatient (IPPS), Outpatient (OPPS) DRG, APC and NTAP Policies, along with the general acute care hospital spending environment. We also assess Budget, Pandemic and Bioterror Funding bills, as they may impact medtech companies via additional funding mechanisms. Precision medicine policies allow the right medicine to be delivered to the right person at the right time; we monitor sequencing initiatives such as NIH’s All of Us. We also geek out on the newest developments in medical technology e.g., liquid biopsy & synthetic biology, to name a few. We look at how private payers and expanding government programs — such as Medicaid and ACA expansions — impact medical technologies, as well as keep a finger on the pulse as to how FDA is classifying and regulating digital technologies, lab developed tests. Sometimes surprise policies — like labor input policies — will drastically swing payment rates for surgical technologies in the physician office: We highlight those policies, as well as others that are likely to be finalized, delayed, phased-in, or scrapped, as well as business impact.
Our Med Tech Services Include:
Monitoring and analysis of relevant policy, legislation, Executive Orders, and policy recommendations from MedPAC, other bodies, along with likelihood of implementation or finalization.
Monitoring and analysis of FDA (510(k), PMA) and Private insurer / CMS / other (e.g., NICE in UK) reimbursement of new and emerging technologies.
Deep-Dive reports on key policy actions and trends including coverage by Medicare, MA, Commercial, CMS CMMI Pilots (e.g., Radiation Oncology) and other Regulations impacting the innovator communities such as Hospital IPPS, OPPS, Surgery Center (ASC) and Clinical Lab Fee Schedule Regulations as well as NIH Initiatives (All of Us, BRAIN).
Discussions of new, potentially exciting technologies (e.g., synthetic biology, liquid biopsy, pan-cancer testing)
Forward-looking weekly Healthcare Policy catalysts and events
Timely communication including discussions on specific issues of interest
Markets Analysis
Capitol Street helps clients assess competitive position in their industry, along with the macro trends and capital markets perspectives on MedTech companies, both public and private.
Our services for MedTech include:
Analysis of public companies earnings calls & communications
Review of capital markets’ perspective on industry trends, what is likely to be impactful or relevant going forward based on our policy expertise, political winds (i.e., is there an upcoming election), must-pass legislation & other sometimes seemingly irrelevant inputs.
